0001601830FALSE00016018302025-03-152025-03-15

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 15, 2025

RECURSION PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)

Delaware
001-40323
 46-4099738
(State or other jurisdiction of incorporation)(Commission File Number)(I.R.S. Employer Identification No.)
41 S Rio Grande Street
Salt Lake City, UT 84101
(Address of principal executive offices) (Zip code)

(385) 269 - 0203
(Registrant’s telephone number, including area code)

Not Applicable
(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading symbol(s)Name of each exchange on which registered
Class A Common Stock, par value $0.00001 per shareRXRX
Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).



Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officer.

Appointment of Directors

On March 15, 2025, the Board of Directors (the “Board”) of Recursion Pharmaceuticals, Inc. (the “Company”), upon the recommendation from its Nominating and Corporate Governance Committee (the “Nominating Committee”), increased the number of members of the Board from 8 to 10 and appointed each of Elaine Sun and Dr. Namandjé Bumpus to the Board, effective immediately.

The Board appointed Ms. Sun as a Class III Director of the Board, with her initial term to extend until the 2027 Annual Meeting of Stockholders, and appointed her as the Chair of the Audit Committee of the Board and as a member of the Compensation Committee of the Board.

The Board appointed Dr. Bumpus as a Class III Director of the Board, with her initial term to extend until the 2027 Annual Meeting of Stockholders, and appointed her as a member of the Nominating Committee of the Board, the Research and Development Committee of the Board, and the Technology Committee of the Board.

As non-employee directors, each of Ms. Sun and Dr. Bumpus will receive cash and equity compensation paid by the Company pursuant to the Recursion Pharmaceuticals, Inc. Outside Director Compensation Policy (the “Director Compensation Policy”), amended as described below, and each will enter into an indemnification agreement with the Company on the Company’s standard form of indemnification agreement for officers and directors.

There are no transactions in which either Ms. Sun or Dr. Bumpus has a direct or indirect material interest requiring disclosure under Item 404(a) of Regulation S-K and there are no arrangements or understandings between either of Ms. Sun or Dr. Bumpus and any other person pursuant to which either director was selected as a director of the Company.

Amendment to the Director Compensation Policy

Also on March 15, 2025, the Board established two new committees of the Board, the Research and Development Committee and the Technology Committee, and amended the Director Compensation Policy to provide compensation terms for members of such committees. The amended Director Compensation Policy is included as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 7.01. Regulation FD Disclosure.

On March 18, 2025, the Company issued a press release announcing the appointment of Ms. Sun and Dr. Bumpus to the Board. A copy of the press release is attached hereto as Exhibit 99.1.

The information furnished in this Item 7.01 (including Exhibit 99.1), shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.


Item 8.01. Other Events.

On March 15, 2025, the Board, upon the recommendation from its Nominating Committee, made certain changes to the composition of its committees, including those described in Item 5.02 of this Current Report on Form 8-K. The resulting composition of the Committees of the Board is as follows:

Audit Committee:Elaine Sun (Chair)
Blake Borgeson
Zavain Dar
Compensation Committee:Robert Hershberg (Chair)
Zachary Bogue
Elaine Sun
Nominating and Corporate Governance Committee:Zavain Dar (Chair)
Blake Borgeson
Namandjé Bumpus
Strategic Transactions and Finance Committee:Christopher Gibson (Chair)
Robert Hershberg
Zavain Dar
Research and Development
Committee:		Franziska Michor (Chair)
Robert Hershberg
Dean Li
Namandjé Bumpus
Technology Committee:Blake Borgeson (Chair)
Zavain Dar
Namandjé Bumpus
Franziska Michor
Corporate Social Responsibility Committee:Christopher Gibson (Chair)
Zachary Bogue
Blake Borgeson
Zavain Dar
ATM Pricing Committee:Chris Gibson
Robert Hershberg
Zavain Dar



Item 9.01. Financial Statements and Exhibits.

(d) Exhibits
Exhibit NumberDescription
10.1
99.1
104Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized on March 18, 2025.

RECURSION PHARMACEUTICALS, INC.
By:
/s/ Christopher Gibson
Christopher Gibson
Chief Executive Officer

EXHIBIT 10.1
RECURSION PHARMACEUTICALS, INC.
OUTSIDE DIRECTOR COMPENSATION POLICY
Recursion Pharmaceuticals, Inc. (the “Company”) believes that providing cash and equity compensation to members of its Board of Directors (the “Board,” and members of the Board, the “Directors”) represents an effective tool to attract, retain and reward Directors who are not employees of the Company (the “Outside Directors”). This Outside Director Compensation Policy (this “Policy”) is intended to formalize the Company’s policy regarding the compensation to its Outside Directors. Unless defined in this Policy, capitalized terms used in this Policy will have the meaning given to such terms in the Company’s 2021 Equity Incentive Plan (the “Plan”), or if the Plan is no longer in place, the meaning given to such terms or any similar terms in the equity plan then in place. Each Outside Director will be solely responsible for any tax obligations incurred by such Outside Director as a result of the equity and cash payments such Outside Director receives under this Policy.
This Policy, as amended, will be effective as of the date of approval by the Board (such date, the “Effective Date”).
1.Cash Compensation.
Annual Cash Retainer
Each Outside Director will be paid an annual cash retainer of $35,000. There are no per-meeting attendance fees for attending Board meetings.
Committee Annual Cash Retainer
Effective as of the Effective Date, each Outside Director who serves as the chair of the Board, or the chair or a member of a committee of the Board listed below will be eligible to earn additional annual cash retainers as follows:
Chair of the Board:$30,000
Chair of the Audit Committee:$20,000
Member of the Audit Committee:$10,000
Chair of the Compensation Committee:$15,000
Member of the Compensation Committee:$7,500
Chair of the Nominating and Corporate Governance Committee:$10,000
Member of the Nominating and Corporate Governance Committee:$5,000
Chair of the Research and Development Committee:$10,000
Member of the Research and Development Committee:$5,000


Chair of the Technology Committee:$10,000
Member of the Technology Committee:$5,000
For clarity, each Outside Director who serves as the chair of a committee will receive only the annual cash retainer as the chair of the committee, and not the additional annual cash retainer as a member of the committee.
Payment
Subject to the section below entitled “Election to Receive Fully Vested Stock,” each annual cash retainer payable under this Policy for service on the Board, chair of the Board, or the chair or a member of a committee of the Board (an “Annual Cash Retainer”) will be paid quarterly in arrears on a prorated basis to each Outside Director who has served in the relevant capacity at any point during the fiscal quarter, and such payment will be made on the last business day of such fiscal quarter (or as soon thereafter as practical, but in no event later than 30 days following the end of such fiscal quarter). For purposes of clarification, an Outside Director who has served as an Outside Director and/or as a member of an applicable committee (or chair thereof) during only a portion of the relevant Company fiscal quarter will receive a pro-rated payment of the quarterly payment of the applicable annual cash retainer(s), calculated based on the number of days during such fiscal quarter such Outside Director has served in the relevant capacities.
Election to Receive Fully Vested Stock
Subject to complying with the Retainer Award Election Mechanics below, each Outside Director may elect to convert all of his or her Annual Cash Retainer with respect to services performed in a future calendar year and otherwise scheduled to be paid following the completion of those services into an award of fully-vested Shares granted under the Plan (“Retainer Award” and such election, a “Retainer Award Election”). If an Outside Director elects to convert his or her Annual Cash Retainer into a Retainer Award, the Retainer Award will be issued automatically and quarterly (such portion of the Retainer Award, a “Quarterly Retainer Award”) in arrears on a prorated basis on the first Trading Day following the end of such immediately preceding Fiscal Quarter. The number of Shares subject to a Quarterly Retainer Award will be determined by dividing the amount of the Annual Cash Retainer that would otherwise be payable with respect to such immediately preceding Fiscal Quarter by the Fair Market Value of a Share on the issuance date (as determined in accordance with the Plan), rounded to the nearest whole Share using standard rounding principles. The “Retainer Award Election Mechanics” are set forth below.
Each Retainer Award Election must be submitted to the Company’s General Counsel in the form and manner specified by the Board or Compensation Committee. An individual who fails to make a timely Retainer Award Election shall not receive a Retainer Award for the next calendar year, and instead shall receive the applicable Annual Cash Retainer for such calendar year. Once a Retainer Award Election is validly submitted, it will remain in effect with respect to all subsequent Annual Cash Retainers related to future calendar years unless the applicable Outside Director revokes such election as provided herein.
-2-

Retainer Award Elections must comply with the following timing requirements:
(a)    Initial Election. Each individual who first becomes an Outside Director following the Effective Date (the date such individual first becomes an Outside Director, the “Initial Director Date”) may make a Retainer Award Election with respect to Annual Retainer Cash Payments payable to such Outside Director in the following calendar year (the “Initial Election”). The Initial Election must be submitted to the Company’s General Counsel within the Company’s next open trading window following the Initial Director Date that occurs in the same calendar year (the last day of such trading window, the “Initial Election Deadline”), and the Initial Election shall become irrevocable effective as of the Initial Election Deadline, provided that if no open trading window occurs in the same calendar year following the Initial Director Date, such Outside Director will not be eligible to make an Initial Election in such calendar year.
(b)    Annual Election. Following the calendar year containing the Initial Director Date, each Outside Director may make a Retainer Award Election with respect to Annual Retainer Cash Payments payable to such Outside Director in the following calendar year (the “Annual Election”). The Annual Election must be submitted to the Company’s General Counsel within the Company’s fourth quarter open trading window (the “Fourth Quarter Trading Window”) of the calendar year preceding the calendar year to which the Annual Retainer Cash Payments relate (the last day of such trading window, the “Annual Election Deadline”), and, except as provided in subsection (d) below, the Annual Election shall become irrevocable effective as of the Annual Election Deadline, provided that if such calendar year does not contain a Fourth Quarter Trading Window, Outside Directors will not be eligible to make an Annual Election in such calendar year.
(c)    Revocation. Following the calendar year containing the Initial Director Date, an Outside Director may revoke his or her Retainer Award Election during a Fourth Quarter Trading Window with respect to Annual Retainer Cash Payments related to future calendar years. If a calendar year does not contain a Fourth Quarter Trading Window, Outside Directors will not be eligible to revoke a Retainer Award Election in such calendar year.
2.Equity Compensation.
Outside Directors will be eligible to receive all types of Awards (except Incentive Stock Options) under the Plan (or the applicable equity plan in place at the time of grant), including discretionary Awards not covered under this Policy. All grants of Awards to Outside Directors pursuant to Section 2 of this Policy will be automatic and nondiscretionary, except as otherwise provided herein, and will be made in accordance with the following provisions:
(a)    No Discretion. No person will have any discretion to select which Outside Directors will be granted any Awards under this Policy or to determine the number of Shares to be covered by such Awards.
(b)    Initial Awards. Each individual who first becomes an Outside Director following the Effective Date will be granted the following awards (each, an “Initial Award”):
-3-

(i)    an option to purchase a number of Shares, with such option having a grant date fair value (determined in accordance with U.S. generally accepted accounting principles) (the “Grant Value”) equal to $250,000, rounded to the nearest whole Share; and
(ii)    an award of restricted stock units covering a number of Shares, with such award having a Grant Value equal to $250,000, rounded to the nearest whole Share.
Each individual’s Initial Award will be granted on the first trading date on or after the Initial Director Date, whether through election by the stockholders of the Company or appointment by the Board to fill a vacancy. If an individual was a member of the Board and also an employee, becoming an Outside Director due to termination of employment will not entitle the Outside Director to any Initial Awards.
Subject to Section 3 of this Policy, each Initial Award will vest as to 1/3rd of the Shares subject to the Initial Award on the first three anniversaries of the Initial Director Date, subject to the Outside Director continuing to be a Service Provider through the applicable vesting date.
(c)    Annual Award. Subject to the following paragraph, on the date of each annual meeting of the Company’s stockholders following the Effective Date (each, an “Annual Meeting”), each Outside Director will be automatically granted the following awards (each, an “Annual Award”):
(i)    an option to purchase a number of Shares, with such option having a Grant Value of $112,500, rounded to the nearest whole Share; and
(ii)    an award of restricted stock units covering a number of Shares, with such award having a Grant Value of $112,500, rounded to the nearest whole Share.
Notwithstanding the foregoing, (i) if an Outside Director’s Initial Awards were granted more than 3 months before an Annual Meeting but within 6 months of such Annual Meeting, the Grant Value of each Annual Award granted to the Outside Director on the date of such Annual Meeting will be reduced by 50%, and (ii) if an Outside Director’s Initial Awards were granted within 3 months before an Annual Meeting, the Outside Director will not receive any Annual Awards on the date of such Annual Meeting.
Subject to Section 3 of this Policy, each Annual Award will vest on the earlier of (i) the first anniversary of the date the Annual Award is granted or (ii) the day prior to the date of the Annual Meeting next following the date the Annual Award was granted, in each case, subject to the Outside Director continuing to be a Service Provider through the applicable vesting date.
(d)    Additional Terms of Initial Awards and Annual Awards. The terms and conditions of each Initial Award and Annual Award will be as follows.
(i)    The term of each Initial Award and Annual Award that is granted as an option will be ten (10) years, subject to earlier termination as provided in the Plan;
-4-

(ii)    The per Share exercise price of each Initial Award and Annual Award that is granted as an option will equal one hundred percent (100%) of the Fair Market Value per Share on such Award’s grant date; and
(iii)     Each Initial Award and Annual Award will be granted under and subject to the terms and conditions of the Plan and the applicable form of Award Agreement previously approved by the Board or its Committee, as applicable, for use thereunder.
3.Change in Control.
Immediately prior to a Change in Control, each Outside Director will fully vest in and have the right to exercise Options and/or Stock Appreciation Rights as to all of the Shares underlying such Award, including those Shares which would not be vested or exercisable, all restrictions on Restricted Stock and Restricted Stock Units will lapse, and, with respect to Awards with performance-based vesting, all performance goals or other vesting criteria will be deemed achieved at 100% of target levels and all other terms and conditions met, unless specifically provided otherwise under the applicable Award Agreement or other written agreement between the Outside Director and the Company or any of its Subsidiaries or Parents, as applicable.
4.Annual Compensation Limit.
No Outside Director may be paid, issued or granted, in any Fiscal Year, cash compensation and equity compensation (including any Awards) following the Effective Date with an aggregate value greater than $850,000 for an Outside Director’s first year of service or $600,000 in any subsequent year. The value of each equity compensation award will be based on its Grant Value for purposes of the limitation under this Section 4). Any cash compensation paid or equity compensation award (including any Awards) granted to an individual for his or her services as an Employee, or for his or her services as a Consultant (other than as an Outside Director), will not count for purposes of the limitation under this Section 4.
5.Travel Expenses.
Each Outside Director’s reasonable, customary and documented travel expenses to Board or Board committee meetings or related to his or her Board service will be reimbursed by the Company.
6.Additional Provisions.
    All provisions of the Plan not inconsistent with this Policy will apply to Awards granted to Outside Directors.
7.Section 409A.
    In no event will cash compensation or expense reimbursement payments under this Policy be paid after the later of (i) 15th day of the 3rd month following the end of the Fiscal Year in which the compensation is earned or expenses are incurred, as applicable, or (ii) 15th day of the 3rd month following the end of the calendar year in which the compensation is earned or expenses are
-5-

incurred, as applicable, in compliance with the “short-term deferral” exception under Section 409A of the Internal Revenue Code of 1986, as amended, and the final regulations and guidance thereunder, as may be amended from time to time (together, “Section 409A”). It is the intent of this Policy that this Policy and all payments hereunder be exempt from or otherwise comply with the requirements of Section 409A so that none of the compensation to be provided hereunder will be subject to the additional tax imposed under Section 409A, and any ambiguities or ambiguous terms herein will be interpreted to be so exempt or comply. In no event will the Company have any liability or obligation to reimburse, indemnify, or hold harmless an Outside Director (or any other person) for any taxes or costs that may be imposed on or incurred by an Outside Director (or any other person) as a result of Section 409A.
8.Stockholder Approval.
Unless otherwise required by applicable law, this Policy will not be subject to approval by the Company’s stockholders, including, for the avoidance of doubt, as a result of or in connection with an action taken with respect to this Policy as contemplated in Section 9 hereof.
9.Revisions.
    The Board may amend, alter, suspend or terminate this Policy at any time and for any reason. No amendment, alteration, suspension or termination of this Policy will materially impair the rights of an Outside Director with respect to compensation that already has been paid or awarded, unless otherwise mutually agreed between the Outside Director and the Company. Termination of this Policy will not affect the Board’s or the Compensation Committee’s ability to exercise the powers granted to it under the Plan with respect to Awards granted under the Plan pursuant to this Policy prior to the date of such termination.
-6-
EXHIBIT 99.1
Recursion Bolsters Board of Directors with Former FDA Principal Deputy Commissioner Dr. Namandjé Bumpus and Mammoth Biosciences COO and CFO Elaine Sun

Dr. Bumpus brings deep experience in scientific innovation and regulatory strategy, while Elaine Sun adds extensive leadership in life sciences finance and corporate strategy.

SALT LAKE CITY, Mar 18, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced that Namandjé Bumpus, Ph.D, and Elaine Sun have been appointed to Recursion’s Board of Directors, effective as of March 15th.

“I am delighted to welcome Elaine and Namandjé to Recursion’s board,” said Chris Gibson, Ph.D., Recursion Co-Founder and CEO. “As the company continues to grow its clinical pipeline and enhance its platform, our new board members’ scientific, clinical, business and financial expertise will be an incredible resource in support of our continued success.”

Dr. Namandjé N. Bumpus served as the FDA’s Principal Deputy Commissioner until December 31, 2024, after joining the agency in August 2022 as Chief Scientist. As Principal Deputy Commissioner she played a pivotal role in shaping the agency’s strategic direction and driving its day-to-day operations. She worked closely with the FDA Commissioner to spearhead key public health initiatives, strengthening regulatory frameworks, modernizing enterprise systems, and enhancing laboratory testing capabilities. She was also one of the foremost drivers of strategy for integration of AI into regulatory science at the agency. Prior to the FDA, Dr. Bumpus was an endowed professor and chair of the Department of Pharmacology and Molecular Sciences at Johns Hopkins University School of Medicine, where she also served as an associate dean. She earned a Ph.D. in pharmacology from the University of Michigan and completed a postdoctoral fellowship at The Scripps Research Institute. Her prior research has spanned across drug metabolism, drug-induced toxicity, mass spectrometry, and infectious disease pharmacology. Dr. Bumpus has received several honors, including the Presidential Early Career Award, the John J. Abel Award, and the Leon I. Goldberg Award, and is a fellow of the American Association for the Advancement of Science and a member of the National Academy of Medicine.
"I’m proud to join Recursion’s board and contribute to its innovative approach to drug discovery and development,” said Dr. Bumpus, “I look forward to bringing the full scope of my experience as a scientist and a leader to help guide the company’s scientific approach and advance its impact on patients’ lives."

Elaine Sun is a 30-year life sciences and financial industry veteran with a track record of building and creating value for early- to late-stage biopharmaceutical companies. She is currently the Chief Operating Officer and Chief Financial Officer at Mammoth Biosciences, an in vivo gene editing therapeutics company co-founded by Nobel laureate and CRISPR pioneer Jennifer Doudna. She previously was SVP and CFO at Halozyme Therapeutics, a commercial-stage biotechnology company, and served as CFO and Chief Strategy Officer at SutroVax (now


Vaxcyte), a developer of innovative vaccines. Earlier in her career, she advised pharmaceutical, biotechnology and medical device companies on M&A and financing transactions valued in excess of $50 billion, including as Managing Director at Evercore Partners and Merrill Lynch. Ms. Sun currently serves on the Board of Dynavax Technologies (NASDAQ:DVAX), a commercial-stage vaccines company as well as Asher Biotherapeutics, a clinical-stage precision oncology company, and holds a BA from Wellesley College and an MBA from Harvard Business School.
"I am excited to support Recursion’s commitment to merging rigorous science with cutting-edge technology to accelerate drug discovery and development and reshape the industry,” said Ms. Sun, “It is truly inspiring, and I look forward to helping Recursion scale its impact and bring new, life-changing therapies to the market."

Rob Hershberg, MD/Ph.D., Recursion’s Chairman, added, “I am delighted to have such phenomenal additions to our Board at such an exciting time for Recursion. I speak for the entire Board when I say we are thrilled to strengthen the company's strategic leadership with these outstanding additions. Welcome Namandjé and Elaine!”

To learn more about Recursion’s Board of Directors, please visit: https://www.recursion.com/team

About Recursion

Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to radically improve lives. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously generate one of the world’s largest proprietary biological and chemical datasets. Recursion leverages sophisticated machine-learning algorithms to distill from its dataset a collection of trillions of searchable relationships across biology and chemistry unconstrained by human bias. By commanding massive experimental scale — up to millions of wet lab experiments weekly — and massive computational scale — owning and operating one of the most powerful supercomputers in the world, Recursion is uniting technology, biology and chemistry to advance the future of medicine.

Recursion is headquartered in Salt Lake City, where it is a founding member of BioHive, the Utah life sciences industry collective. Recursion also has offices in Toronto, Montréal, New York, London, Oxford area, and the San Francisco Bay area. Learn more at recursion.com, or connect on X (formerly Twitter) and LinkedIn.

Media Contact
Media@Recursion.com

Investor Contact
Investor@Recursion.com



Forward-Looking Statements
This document contains information that includes or is based upon "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995, including, without limitation, those regarding Recursion’s growth; Recursion’s leadership of the TechBio space; early and late stage discovery, preclinical, and clinical programs; licenses and collaborations; prospective products and their potential future indications and market opportunities; Recursion OS and other technologies; business and financial plans and performance; and all other statements that are not historical facts. Forward-looking statements may or may not include identifying words such as “plan,” “will,” “expect,” “anticipate,” “intend,” “believe,” “potential,” “continue,” and similar terms. These statements are subject to known or unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements, including but not limited to: challenges inherent in pharmaceutical research and development, including the timing and results of preclinical and clinical programs, where the risk of failure is high and failure can occur at any stage prior to or after regulatory approval due to lack of sufficient efficacy, safety considerations, or other factors; our ability to leverage and enhance our drug discovery platform; our ability to obtain financing for development activities and other corporate purposes; the success of our collaboration activities; our ability to obtain regulatory approval of, and ultimately commercialize, drug candidates; our ability to obtain, maintain, and enforce intellectual property protections; cyberattacks or other disruptions to our technology systems; our ability to attract, motivate, and retain key employees and manage our growth; inflation and other macroeconomic issues; and other risks and uncertainties such as those described under the heading “Risk Factors” in our filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K for the Fiscal Year Ended December 31, 2024. All forward-looking statements are based on management’s current estimates, projections, and assumptions, and Recursion undertakes no obligation to correct or update any such statements, whether as a result of new information, future developments, or otherwise, except to the extent required by applicable law.



v3.25.1
Cover
Mar. 15, 2025
Cover [Abstract]  
Document Type 8-K
Document Period End Date Mar. 15, 2025
Entity Registrant Name RECURSION PHARMACEUTICALS, INC.
Entity Incorporation, State or Country Code DE
Entity File Number 001-40323
Entity Tax Identification Number 46-4099738
Entity Address, Address Line One 41 S Rio Grande Street
Entity Address, City or Town Salt Lake City,
Entity Address, State or Province UT
Entity Address, Postal Zip Code 84101
City Area Code 385
Local Phone Number 269 - 0203
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Class A Common Stock, par value $0.00001 per share
Trading Symbol RXRX
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Entity Central Index Key 0001601830
Amendment Flag false
Grafico Azioni Recursion Pharmaceuticals (NASDAQ:RXRX)
Storico
Da Mar 2025 a Apr 2025 Clicca qui per i Grafici di Recursion Pharmaceuticals
Grafico Azioni Recursion Pharmaceuticals (NASDAQ:RXRX)
Storico
Da Apr 2024 a Apr 2025 Clicca qui per i Grafici di Recursion Pharmaceuticals